Metabolism of bromopride in mouse, rat, rabbit, dog, monkey, and human hepatocytes

Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 6, 2013, Pages 453-461

  Dunne, Christine E ^a   Bushee, Jennifer L ^b   Argikar, Upendra A ^b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Biotransformation; Bromopride; Hepatocytes; High resolution mass spectrometry; LC MSn; Metabolite identification

Indexed keywords

BROMOPRIDE; DRUG METABOLITE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOG; DRUG TRANSFORMATION; HAPLORHINI; HUMAN; HUMAN CELL; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER CELL; MALE; MASS SPECTROMETRY; MEASUREMENT ACCURACY; MOUSE; NONHUMAN; RABBIT; RAT;

ANIMALS; BIOTRANSFORMATION; CHROMATOGRAPHY, LIQUID; DOGS; FEMALE; HEPATOCYTES; HUMANS; MALE; MASS SPECTROMETRY; METOCLOPRAMIDE; MICE; RABBITS; RATS;

EID: 84893011108     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-13-RG-010     Document Type: Article

References (26)

1. Ferraù, O., Pustorino, S., Luzza, G., Turiano, S., Familiari, L., Fanfani, A., Iadevaia, V., Mandelli, V. and Orlando, N.: Changes induced with bromopride and metoclopramide in the kinetics of gastric emptying in patients with gastric motor hyposthenia. Comparison with placebo. Clin. Ter., 99: 63-71 (1981)
2. Roila, F., Minotti, V., Ballatori, E., Basurto, C. and Tonato, M.: Evaluation of the antiemetic activity of bromopride in cancer patients treated with i.v. CMF. Tumori, 71: 455-458 (1985)
3. Tonini, M., Cipollina, L., Poluzzi, E., Crema, F., Corazza, G. R. and De Ponti, F.: Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment. Pharmacol. Ther., 19: 379-390 (2004)
4. Nasello, A. G., Gidali, D., de Sa-Rocha, L. C. and Felicio, L. F.: Differential effects of bromopride and domperidone on cholinesterase activity in rat tissues. Life Sci., 56: 151-156 (1995)
5. Bergonzini, R. and Sardo, P.: Double-blind clinical studies of the effect of bromopride on gastric emptying. Clin. Ter., 99: 637-641 (1981)
6. Fischer, M., Jesau, R. and Tinhof, W.: Management of gastrointestinal diseases using a motility-regulating preparation. Results of a field study using bromopride (Viaben) conducted by 530 general practitioners on 4182 patients. Fortschr. Med., 97: 883-888 (1979).
7. Fontaine, J. and Reuse, J.: Pharmacological analysis of the effects of substituted benzamides on the isolated guinea-pig ileum. Study of metoclopramide, sulpiride, bromopride, tiapride and sultopride. Arch. Int. Pharmacodyn. Ther., 235: 51-61 (1978)
8. Becker, K., Eckardt, V. F. and Sinterhauf, K.: Der Effekt von Bromoprid auf die Sauresekretion des Magens. Arzneimittelforschung, 30: 1926- 1928 (1980)[Effect of bromopride on gastric acid secretion (authors' translation)]
9. Brodie, R. R., Chasseaud, L. F., Darragh, A., Lambe, R. F., Rooney, L. and Taylor, T.: Pharmacokinetics and bioavailability of the anti-emetic agent bromopride. Biopharm. Drug Dispos., 7: 215-222 (1986)
10. Imbs, J., Leibenguth, A., Koffel, J. C. and Jung, L.: Bromoprid: metabolismus und renale Ausscheidung beim Hund. Arzneimittelforschung, 32: 503-508 (1982)[Bromopride: metabolism and urinary elimination in dogs (authors' translation)]
11. Jung, L., Imbs, J. and Koffel, J. C.: Bromoprid: Pharmakokinetik beim Hund. Arzneimittelforschung, 32: 509-511 (1982)[Bromopride: pharmacokinetic s in dogs (authors' translation)]
12. Lücker, P. W., Tinhof, W., Wetzelsberger, N., Weyers, W. and Brodbeck, R.: Pharmakokinetik und absolute Bioverfugbarkeit von Bromoprid aus verschiedenen pharmazeutischen Formulierungen. Arzneimittelforschung, 33: 453-458 (1983)[Pharmacokinetics and absolute bioavailability of bromopride from various pharmaceutical formulations (authors' translation)].
13. Shaffer, C. L., Gunduz, M., O'Connell, T. N., Obach, R. S. and Yee, S.: Biotransformation of a GABAA receptor partial agonist in spraguedawley rats and cynomolgus monkeys: identification of two unique Ncarbamoyl metabolites. Drug Metab. Dispos., 33: 1688-1699 (2005)
14. Gunduz, M., Argikar, U. A., Baeschlin, D., Ferreira, S., Hosagrahara, V. and Harriman, S.: Identification of a novel N-carbamoyl glucuronide: in vitro, in vivo, and mechanistic studies. Drug Metab. Dispos., 38: 361- 367 (2010)
15. Argikar, U. A., Cloyd, J. C., Birnbaum, A. K., Leppik, I. E., Conway, J., Kshirsagar, S., Oetting, W. S., Klein, E. C. and Remmel, R. P.: Paradoxical urinary phenytoin metabolite (S)/(R) ratios in CYP2C19*1/*2 patients. Epilepsy Res., 71: 54-63 (2006).
16. Sinz, M. W. and Remmel, R. P.: Isolation and characterization of a novel quaternary ammonium-linked glucuronide of lamotrigine. Drug Metab. Dispos., 19: 149-153 (1991)
17. Bushee, J. L. and Argikar, U. A.: An experimental approach to enhance precursor ion fragmentation for metabolite identification studies: application of dual collision cells in an orbital trap. Rapid Commun. Mass Spectrom., 25: 1356-1362 (2011).
18. Lira, R. P., Moraes, L. F., Oliveira Junior, M., Melo, A. L. and Vasconcelos, M. S.: Influence of bromopride in the prophylaxis of nausea associated with fluorescein angiography. Arq. Bras. Oftalmol., 70: 105- 108 (2007)
19. Brodie, R. R., Chasseaud, L. F. and Rooney, L.: Determination of bromopride in human plasma and urine by high-performance liquid chromatography. J. Chromatogr. A, 310: 353-360 (1984)
20. Nazare, P., Massaroti, P., Duarte, L. F., Campos, D. R., Marchioretto, M. A., Bernasconi, G., Calafatti, S., Barros, F. A., Meurer, E. C., Pedrazzoli, J. and Moraes, L. A.: Validated method for determination of bromopride in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to the bioequivalence study. J. Mass Spectrom., 40: 1197-1202 (2005)
21. Argikar, U. A., Gomez, J., Ung, D., Parkman, H. P. and Nagar, S.: Identification of novel metoclopramide metabolites in humans: in vitro and in vivo studies. Drug Metab. Dispos., 38: 1295-1307 (2010)
22. Bateman, D. N.: Clinical pharmacokinetics of metoclopramide. Clin. Pharmacokinet., 8: 523-529 (1983)
23. Bakke, O. M. and Segura, J.: The absorption and elimination of metoclopramide in three animal species. J. Pharm. Pharmacol., 28: 32- 39 (1976)
24. Cowan, D. A., Huizing, G. and Beckett, A. H.: Identification of four new metabolic products of metoclopramide using mass spectrometry. Xenobiotica, 6: 605-616 (1976).
25. Bateman, D. N. and Davies, D. S.: Pharmacokinetics of metoclopramide. Lancet, 1: 166 (1979)
26. Nowell, S. A., Massengill, J. S., Williams, S., Radominska-Pandya, A., Tephly, T. R., Cheng, Z., Strassburg, C. P., Tukey, R. H., MacLeod, S. L., Lang, N. P. and Kadlubar, F. F.: Glucuronidation of 2-hydroxyamino-1- methyl-6-phenylimidazo[4,5-b]pyridine by human microsomal UDPglucuronosyltransferases:identification of specific UGT1A family isoforms involved. Carcinogenesis, 20: 1107-1114 (1999)